AIM ImmunoTech arrives at its May 18 earnings event in a deeply compromised technical state — the stock has fallen 56% over the past month to $0.253, and Q1 results released late Friday only deepened the concern, with EPS of $(0.69) against a year-ago $(0.05) and revenue of $22K missing the $100K estimate badly.
The borrow market tells an equally striking story, though one that has shifted sharply in recent days. Cost to borrow peaked above 340% in early April and has since eased to roughly 191% — still an extraordinarily punishing rate for anyone maintaining a short position. Short interest as a percentage of free float is 7.1%, and while that rose 56% over the past month as bearish conviction built, the last week has seen it fall 22% as short sellers reduced positions. Availability has loosened dramatically: utilisation dropped from above 75% to just under 10% in two sessions this week, signalling a significant release of borrowed shares back into the lending pool. The retreat in shorts and availability loosening comes just as the stock hit fresh lows — a pattern more consistent with short covering on the way down than with new positioning ahead of the print.
The debate around AIM is fundamentally about clinical viability versus financial survival. Bulls point to Ampligen's pipeline across colorectal cancer, pancreatic cancer, and post-COVID indications, with a Phase 2a colorectal study cited as a meaningful near-term catalyst. The company also exercised warrants this month to raise approximately $4.2 million in gross proceeds, providing a modest liquidity bridge. Bears have the harder data: a net loss of $3.3 million, EPS of $(1.57) far beyond internal estimates, and a pattern of accelerating losses. Ascendiant Capital's Edward Woo has maintained a Buy rating but slashed his target from $22 to $10 in April — the third consecutive reduction in six months, down from $150 in October 2025. The mean analyst target of $10 against a current price of $0.253 implies extraordinary upside on paper, but the repeated and steep target cuts suggest the number is a directional signal rather than a credible near-term anchor.
Past earnings reactions give little comfort for bulls. The last major print in March 2026 sent the stock down 20% on the day and a further 5% over the following week. The November 2025 result produced a similar one-day drop of 5.7%. The one bright spot was a November 2025 event with a 3.8% gain on the day and a 17% five-day rally, suggesting the stock can move sharply in either direction when the clinical narrative catches attention. The short score has also collapsed from above 67 just last week to 47 now — driven by the sharp unwind in utilisation — which means bearish pressure from the lending market has eased into what is already a deeply stressed price.
Monday's print is therefore less a question of quarterly financials and more a test of whether the Ampligen clinical programme carries enough near-term credibility to arrest a stock that has lost more than half its value in a single month.
See the live data behind this article on ORTEX.
Open AIM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
